{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:56:26Z","timestamp":1780541786552,"version":"3.54.1"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health University of California San Diego Clinical and Translational Science Award","award":["UL1TR001442"],"award-info":[{"award-number":["UL1TR001442"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Parkinson disease (PD) psychosis (PDP) is a disabling non-motor symptom. Pharmacologic treatment is limited to pimavanserin, quetiapine, and clozapine, which do not worsen parkinsonism. A Food and Drug Administration black box warning exists for antipsychotics, suggesting increased mortality in elderly patients with dementia. However, the reasons for higher mortality are unknown.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Aim<\/jats:title>\n<jats:p>Expanding on prior work exploring mortality in treated PDP patients, we conducted a retrospective comparison to understand the links between treatment regimen, clinical characteristics, and negative outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Electronic medical record data extraction included clinically diagnosed PD patients between 4\/29\/16-4\/29\/19 and excluded patients with primary psychiatric diagnoses or atypical parkinsonism. Mortality and clinical characteristics during the study period were compared between untreated patients and those receiving pimavanserin, quetiapine, or both agents (combination). Mortality analyses were adjusted for age, sex, levodopa equivalent daily dose (LEDD), and dementia.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>The pimavanserin group (n = 34) had lower mortality than the untreated group (n = 66) (odds ratio = 0.171, 95% confidence interval: 0.025\u20130.676, <jats:italic>p<\/jats:italic> = 0.026). The untreated group had similar mortality compared to the quetiapine (n = 147) and combination (n = 68) groups. All treated groups had a higher LEDD compared to the untreated group, but no other differences in demographics, hospitalizations, medical comorbidities, medications, or laboratory values were found between the untreated and treated groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>PDP patients receiving pimavanserin had lower mortality than untreated patients. We found no other clear differences in clinical characteristics to explain the mortality risk. Prospective randomized trials are needed to definitively identify the optimal PDP treatment regimen and associated risks.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0278262","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T18:48:20Z","timestamp":1674845300000},"page":"e0278262","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-2590","authenticated-orcid":true,"given":"Katherine","family":"Longardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenton A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aljoharah","family":"Alakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeri","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2452-4939","authenticated-orcid":true,"given":"Fatta B.","family":"Nahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"issue":"2","key":"pone.0278262.ref001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/JGP.0b013e31821f1b41","article-title":"Prevalence of psychotic symptoms in a community-based Parkinson disease sample.","volume":"20","author":"J Mack","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"pone.0278262.ref002","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archneur.63.5.713","article-title":"The malignant course of \"benign hallucinations\" in Parkinson disease.","volume":"63","author":"CG Goetz","year":"2006","journal-title":"Arch Neurol"},{"issue":"6","key":"pone.0278262.ref003","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.22839","article-title":"The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria","volume":"25","author":"G Fenelon","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"pone.0278262.ref004","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","article-title":"The psychosis spectrum in Parkinson disease","volume":"13","author":"DH Ffytche","year":"2017","journal-title":"Nature reviews Neurology"},{"key":"pone.0278262.ref005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.parkreldis.2019.10.018","article-title":"Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: Retrospective cohort study.","volume":"68","author":"JB Wetmore","year":"2019","journal-title":"Parkinsonism & related disorders."},{"issue":"2","key":"pone.0278262.ref006","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review","volume":"34","author":"K Seppi","year":"2019","journal-title":"Mov Disord"},{"issue":"6","key":"pone.0278262.ref007","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285610389656","article-title":"Quetiapine in the treatment of psychosis in Parkinson\u2019s disease.","volume":"3","author":"P Shotbolt","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"pone.0278262.ref008","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","article-title":"Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease","volume":"73","author":"D Weintraub","year":"2016","journal-title":"JAMA neurology"},{"issue":"17","key":"pone.0278262.ref009","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1212\/WNL.0000000000006396","article-title":"Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine","volume":"91","author":"GM Moreno","year":"2018","journal-title":"Neurology"},{"key":"pone.0278262.ref010","article-title":"Mortality Among Parkinson\u2019s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.","author":"AD Mosholder","year":"2022","journal-title":"Am J Psychiatry."},{"issue":"13","key":"pone.0278262.ref011","doi-asserted-by":"crossref","first-page":"e1266","DOI":"10.1212\/WNL.0000000000012601","article-title":"Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease","volume":"97","author":"YJ Hwang","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"pone.0278262.ref012","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.","volume":"53","author":"ZS Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc."},{"issue":"15","key":"pone.0278262.ref013","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.","volume":"23","author":"CG Goetz","year":"2008","journal-title":"Mov Disord"},{"issue":"8","key":"pone.0278262.ref014","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"EB Forsaa","year":"2010","journal-title":"Archives of Neurology"},{"issue":"6","key":"pone.0278262.ref015","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/mds.25389","article-title":"Risk factors for hallucinations in Parkinson\u2019s disease: results from a large prospective cohort study","volume":"28","author":"K Zhu","year":"2013","journal-title":"Movement Disorders"},{"issue":"15","key":"pone.0278262.ref016","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease","volume":"25","author":"CL Tomlinson","year":"2010","journal-title":"Mov Disord"},{"issue":"2","key":"pone.0278262.ref017","first-page":"34","article-title":"How to dose carbidopa and levodopa extended-release capsules (Rytary).","volume":"1","author":"RA Hauser","year":"2015","journal-title":"Clin Med J."},{"key":"pone.0278262.ref018","author":"RC Team","year":"2013","journal-title":"R: A language and environment for statistical computing"},{"issue":"8","key":"pone.0278262.ref019","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2017.1125","article-title":"Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease","volume":"74","author":"E De Pablo-Fernandez","year":"2017","journal-title":"JAMA neurology"},{"issue":"6","key":"pone.0278262.ref020","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.parkreldis.2014.02.030","article-title":"Survival in Parkinson\u2019s disease. Relation with motor and non-motor features.","volume":"20","author":"LM de Lau","year":"2014","journal-title":"Parkinsonism & related disorders."},{"issue":"11","key":"pone.0278262.ref021","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00702-019-02055-3","article-title":"Motor and non-motor function predictors of mortality in Parkinson\u2019s disease","volume":"126","author":"P Bugalho","year":"2019","journal-title":"Journal of neural transmission"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T18:48:42Z","timestamp":1674845322000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278262"}},"subtitle":[],"editor":[{"given":"Antonina","family":"Luca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0278262","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}